Synergistic Breakthroughs in ADC and Novel Antibody Drug Fields: From Industrial Predicaments to Value Reconstruction at Academic Summits
Synergistic Breakthroughs in ADC and Novel Antibody Drug Fields: From Industrial Predicaments to Value Reconstruction at Academic Summits When Qide Pharmaceutical’s FGFR3 ADC drug GQ1011 completed global licensing with a total transaction amount exceeding $13 billion, the biopharmaceutical industry witnessed once again the immense potential of antibody-drug conjugates (ADCs). Meanwhile, the $8.4 billion collaboration between … Read more